Protein tyrosine phosphatases in autoimmunity

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 29-55

  Vang, Torkel ^a   Miletic, Ana V ^a   Arimura, Yutaka ^a   Tautz, Lutz ^a   Rickert, Robert C ^a   Mustelin, Tomas ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

CD45; LYP; PTPN22

Indexed keywords

CD45 ANTIGEN; DUAL SPECIFICITY PHOSPHATASE 2; ISOPROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 5; PROTEIN SH3; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; REGULATOR PROTEIN; T LYMPHOCYTE RECEPTOR;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; DISEASE PREDISPOSITION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC VARIABILITY; GRAVES DISEASE; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PTPN12 GENE; PTPN18 GENE; PTPN22 GENE; PTPN6 GENE; PTPRC GENE; PTPRN GENE; PTPRN2 GENE; REGULATOR GENE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTIGENS, CD45; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; PROTEIN TYROSINE PHOSPHATASES;

EID: 42649105767     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090418     Document Type: Review

References (152)

1. Rose NR, Mackay IR. 1999. The Autoimmune Diseases. London: Academic
2. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, et al. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:454-60
3. Sakaguchi S, Sakaguchi N, Yoshitomi H, Hata H, Takahashi T, Nomura T. 2006. Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. Semin. Immunol. 18:199-206
4. Chang TT, Kuchroo VK, Sharpe AH. 2002. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease. Curr. Dir. Autoimmun. 5:113-30
5. Vang T, Congia M, Macis MD, Musumeci L, Orru V, et al. 2005. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37:1317-19
6. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, et al. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36:337-38
7. Bottini N, Vang T, Cucca F, Mustelin T. 2006. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18:207-13
8. Nomura T, Sakaguchi S. 2007. Foxp3 and Aire in thymus-generated Treg cells: a link in self-tolerance. Nat. Immunol. 8:333-34
9. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-51
10. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301-6
11. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. 2005. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6:1160-67
12. Grimaldi CM, Hicks R, Diamond B. 2005. B cell selection and susceptibility to autoimmunity. J. Immunol. 174:1775-81
13. Stockinger B. 1999. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol. 71:229-65
14. + regulatory T cells. Nat. Immunol. 4:330-36
15. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:329-41
16. Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191-97
17. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, et al. 2004. Protein tyrosine phosphatases in the human genome. Cell 117:699-711
18. Mustelin T, Vang T, Bottini N. 2005. Protein tyrosine phosphatases and the immune response. Nat. Rev. Immunol. 5:43-57
19. Pao LI, Badour K, Siminovitch KA, Neel BG. 2007. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu. Rev. Immunol. 25:473-523
20. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. 1999. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 93:2013-24
21. Spencer S, Dowbenko D, Cheng J, Li W, Brush J, et al. 1997. PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein that is a substrate for a PEST tyrosine phosphatase. J. Cell Biol. 138:845-60
22. Cote JF, Chung PL, Theberge JF, Halle M, Spencer S, et al. 2002. PSTPIP is a substrate of PTP-PEST and serves as a scaffold guiding PTP-PEST toward a specific dephosphorylation of WASP. J. Biol. Chem. 277:2973-86
23. Matthews RJ, Bowne DB, Flores E, Thomas ML. 1992. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol. Cell. Biol. 12:2396-405
24. Gjorloff-Wingren A, Saxena M, Han S, Wang X, Alonso A, et al. 2000. Subcellular localization of intracellular protein tyrosine phosphatases in T cells. Eur. J. Immunol. 30:2412-21
25. Cloutier JF, Veillette A. 1996. Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J. 15:4909-18
26. Gregorieff A, Cloutier JF, Veillette A. 1998. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J. Biol. Chem. 273:13217-22
27. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D. 2001. A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat. Struct. Biol. 8:998-1004
28. Hill RJ, Zozulya S, Lu YL, Ward K, Gishizky M, Jallal B. 2002. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp. Hematol. 30:237-44
29. Cloutier JF, Veillette A. 1999. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J. Exp. Med. 189:111-21
30. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. 1999. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur. J. Immunol. 29:3845-54
31. Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, et al. 2006. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J. Biol. Chem. 281:11002-10
32. Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A. 2003. Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol. Cell. Biol. 23:2017-28
33. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. 2004. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303:685-89
34. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, et al. 2007. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129:147-61
35. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, et al. 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330-37
36. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, et al. 2004. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53:3020-23
37. Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P. 2004. A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun. 5:678-80
38. Ladner MB, Bottini N, Valdes AM, Noble JA. 2005. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum. Immunol. 66:60-64
39. Orozco G, Eerligh P, Sanchez E, Zhernakova S, Roep BO, et al. 2005. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum. Immunol. 66:1235-41
40. Lee AT, Li W, Liew A, Bombardier C, Weisman M, et al. 2005. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 6:129-33
41. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, et al. 2005. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76:561-71
42. Viken MK, Amundsen SS, Kvien TK, Boberg KM, Gilboe IM, et al. 2005. Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun. 6:271-73
43. Hinks A, Barton A, John S, Bruce I, Hawkins C, et al. 2005. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 52:1694-99
44. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, et al. 2004. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75:504-7
45. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, et al. 2004. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. Endocrinol. Metab. 89:5862-65
46. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, et al. 2006. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59:404-7
47. Canton I, Akhtar S, Gavalas NG, Gawkrodger DJ, Blomhoff A, et al. 2005. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 6:584-87
48. Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, et al. 2005. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum. 52:4039-43
49. Begovich AB, Caillier SJ, Alexander HC, Penko JM, Hauser SL, et al. 2005. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am. J. Hum. Genet. 76:184-87
50. van Oene M, Wintle RF, Liu X, Yazdanpanah M, Gu X, et al. 2005. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 52:1993-98
51. Wagenleiter SE, Klein W, Griga T, Schmiegel W, Epplen JT, Jagiello P. 2005. A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease. Int. J. Immunogenet. 32:323-24
52. Martin MC, Oliver J, Urcelay E, Orozco G, Gomez-Garcia M, et al. 2005. The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease. Tissue Antigens 66:314-17
53. Prescott NJ, Fisher SA, Onnie C, Pattni R, Steer S, et al. 2005. A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population. Tissue Antigens 66:318-20
54. Rueda B, Nunez C, Orozco G, Lopez-Nevot MA, de la Concha EG, et al. 2005. C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition. Hum. Immunol. 66:848-52
55. Milkiewicz P, Pache I, Buwaneswaran H, Liu X, Coltescu C, et al. 2006. The PTPN22 1858T variant is not associated with primary biliary cirrhosis. Tissue Antigens 67:434-37
56. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, et al. 2007. The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology 46:49-56
57. Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, et al. 2005. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 77:567-81
58. Wesoly J, Hu X, Thabet MM, Chang M, Uh H, et al. 2007. The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population. Rheumatology 46:617-21
59. Ikari K, Momohara S, Inoue E, Tomatsu T, Hara M, et al. 2006. Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. Rheumatology 45:1345-48
60. Hinks A, Eyre S, Barton A, Thomson W, Worthington J. 2007. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Ann. Rheum. Dis. 66:683-86
61. Kawasaki E, Awata T, Ikegami II, Kobayashi T, Maruyama T, et al. 2006. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. Am. J. Med. Genet. Part. A 140:586-93
62. Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, et al. 2007. No independent role of the -1123 G>C and +2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res. Clin. Pract. 76:297-303
63. Onengut-Gumuscu S, Buckner JH, Concannon P. 2006. A haplotype-based analysis of the PTPN22 locus in type 1 diabetes. Diabetes 55:2883-89
64. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, et al. 2006. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J. Med. Genet. 43:517-22
65. Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, et al. 2005. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1435 multiplex families. Diabetes 54:2995-3001
66. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-11
67. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, et al. 2005. Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 77:1044-60
68. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. 2006. PTPN22 polymorphism and anticyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res. Ther. 8:R19
69. Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, et al. 2006. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49:1198-208
70. Dieude P, Garnier S, Michou L, Petit-Teixeira E, Glikmans E, et al. 2005. Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele. Arthritis Res. Ther. 7:R1200-7
71. Lie BA, Viken MK, Odegard S, van der Heijden D, Landewe R, et al. 2007. Associations between the PTPN22 1858C>T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann. Rheum. Dis. 66:1604-9
72. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. 2005. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin. Endocrinol. 62:679-82
73. Fedetz M, Matesanz F, Caro-Maldonado A, Smirnov II, Chvorostinka VN, et al. 2006. The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue Antigens 67:430-33
74. Salojin KV, Zhang J, Madrenas J, Delovitch TL. 1998. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. Immunol. Today 19:468-73
75. Salojin K, Zhang J, Cameron M, Gill B, Arreaza G, et al. 1997. Impaired plasma membrane targeting of Grb2-murine son of sevenless (mSOS) complex and differential activation of the Fyn-T cell receptor (TCR)-zeta-Cbl pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice. J. Exp. Med. 186:887-97
76. Delovitch TL, Singh B. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727-38. Erratum. 1998. Immunity 8(4):531
77. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. 1993. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J. Exp. Med. 177:1221-26
78. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445:931-35
79. Chapman SJ, Khor CC, Vannberg FO, Maskell NA, Davies CW, et al. 2006. PTPN22 and invasive bacterial disease. Nat. Genet. 38:499-500
80. Kadioglu A, Andrew PW. 2004. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25:143-49
81. Pertovaara M, Raitala A, Juonala M, Kahonen M, Lehtimaki T, et al. 2007. Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study. Clin. Exp. Immunol. 147:265-69
82. Gomez LM, Anaya JM, Martin J. 2005. Genetic influence of PTPN22 R620W polymorphism in tuberculosis. Hum. Immunol. 66:1242-47
83. Cote JF, Charest A, Wagner J, Tremblay ML. 1998. Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatases using PTP-PEST as a model. Biochemistry 37:13128-37
84. Garton AJ, Flint AJ, Tonks NK. 1996. Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST. Mol. Cell. Biol. 16:6408-18
85. Aoki N, Ueno S, Mano H, Yamasaki S, Shiota M, et al. 2004. Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. J. Biol. Chem. 279:10765-75
86. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, et al. 1996. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat. Genet. 14:199-202
87. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. 2000. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 12:479-86
88. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, et al. 2002. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11:961-69
89. Yang H, Reinherz EL. 2006. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J. Immunol. 176:5898-907
90. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, et al. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA 100:13501-6
91. Hermiston ML, Xu Z, Weiss A. 2003. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 21:107-37
92. Kung C, Pingel JT, Heikinheimo M, Klemola T, Varkila K, et al. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat. Med. 6:343-45
93. Kishihara K, Penninger J, Wallace VA, Kundig TM, Kawai K, et al. 1993. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 74:143-56
94. Cyster JG, Healy JI, Kishihara K, Mak TW, Thomas ML, Goodnow CC. 1996. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381:325-28
95. Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, et al. 2006. CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers. Nat. Immunol. 7:190-98
96. Xu Z, Weiss A. 2002. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat. Immunol. 3:764-71
97. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. 1998. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 279:88-91
98. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, et al. 2000. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103:1059-70
99. Nam HJ, Poy F, Saito H, Frederick CA. 2005. Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J. Exp. Med. 201:441-52. Erratum. 2005. J. Exp. Med. 201(6):1019
100. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. 2005. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23:635-47
101. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, et al. 2000. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat. Genet. 26:495-99
102. Lynch KW, Weiss A. 2001. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem. 276:24341-47
103. Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, et al. 2001. PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. Nat. Genet. 29:23-24
104. Vorechovsky I, Kralovicova J, Tchilian E, Masterman T, Zhang Z, et al. 2001. Does 77C->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus? Nat. Genet. 29:22-23
105. Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, et al. 2003. Enhanced frequency of a PTPRC (CD45) exon A mutation (77C->G) in systemic sclerosis. Genes Immun. 4:168-69
106. Vogel A, Strassburg CP, Manns MP. 2003. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun. 4:79-81
107. Wood JP, Pani MA, Bieda K, Meyer G, Usadel KH, Badenhoop K. 2002. A recently described polymorphism in the CD28 gene on chromosome 2q33 is not associated with susceptibility to type 1 diabetes. Eur. J. Immunogenet. 29:347-49
108. Jacobsen M, Hoffmann S, Cepok S, Stei S, Ziegler A, et al. 2002. A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics 54:158-63
109. Passini N, Larigan JD, Genovese S, Appella E, Sinigaglia F, Rogge L. 1995. The 37/40-kDa autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Proc. Natl. Acad. Sci. USA 92:9412-16
110. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, et al. 1996. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc. Natl. Acad. Sci. USA 93:2307-11
111. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, et al. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445-54
112. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4:124-29
113. Westhoff CM, Whittier A, Kathol S, McHugh J, Zajicek C, et al. 1997. DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. J. Immunol. 159:3024-33
114. Carter JD, Calabrese GM, Naganuma M, Lorenz U. 2005. Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. J. Immunol. 174:6627-38
115. Huck S, Le Corre R, Youinou P, Zouali M. 2001. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33:213-24
116. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, et al. 2005. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br. J. Haematol. 129:791-94
117. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. 2005. STAT3-and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc. Natl. Acad. Sci. USA 102:6948-53
118. Nguyen TV, Ke Y, Zhang EE, Feng GS. 2006. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J. Immunol. 177:5990-96
119. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785-92
120. Kawai S, Goto Y, Ito LS, Oba-Shinjo SM, Uno M, et al. 2006. Significant association between PTPN11 polymorphism and gastric atrophy among Japanese Brazilians. Gastric Cancer 9:277-83
121. Chan RJ, Feng GS. 2007. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109:862-67
122. Mohi MG, Neel BG. 2007. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17:23-30
123. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, et al. 1997. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 186:683-93
124. Zhu W, Mustelin T, David M. 2002. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J. Biol. Chem. 277:35787-90
125. Bauler TJ, Hughes ED, Arimura Y, Mustelin T, Saunders TL, King PD. 2007. Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase. J. Immunol. 178:3680-87
126. Han S, Williams S, Mustelin T. 2000. Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling. Eur. J. Immunol. 30:1318-25
127. Saxena M, Williams S, Brockdorff J, Gilman J, Mustelin T. 1999. Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 274:11693-700
128. Saxena M, Williams S, Gilman J, Mustelin T. 1998. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 273:15340-44
129. Adachi M, Torigoe T, Sekiya M, Minami Y, Taniguchi T, et al. 1995. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. FEBS Lett. 372:113-18
130. Jui HY, Tseng RJ, Wen X, Fang HI, Huang LM, et al. 2000. Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. J. Biol. Chem. 275:41124-32
131. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z. 2003. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol. Cell. Biol. 23:3623-35
132. Liu Y, Shepherd EG, Nelin LD. 2007. MAPK phosphatases - regulating the immune response. Nat. Rev. Immunol. 7:202-12
133. Tanzola MB, Kersh GJ. 2006. The dual specificity phosphatase transcriptome of the murine thymus. Mol. Immunol. 43:754-62
134. Owens DM, Keyse SM. 2007. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26:3203-13
135. Abraham SM, Clark AR. 2006. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem. Soc. Trans. 34:1018-23
136. Suzuki C, Unoki M, Nakamura Y. 2001. Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes. J. Hum. Genet. 46:155-57
137. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, et al. 2006. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat. Immunol. 7:274-83
138. Ym Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422:527-31
139. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, et al. 2004. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430:793-97
140. Kovanen PE, Rosenwald A, Fu J, Hurt EM, Lam LT, et al. 2003. Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J. Biol. Chem. 278:5205-13
141. Mandl M, Slack DN, Keyse SM. 2005. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol. Cell. Biol. 25:1830-45
142. Masuda K, Shima H, Katagiri C, Kikuchi K. 2003. Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK specific phosphatase, at Ser-446. J. Biol. Chem. 278:32448-56
143. Wu Q, Huang S, Sun Y, Gu S, Lu F, et al. 2006. Dual specificity phosphatase 18, interacting with SAPK, dephosphorylates SAPK and inhibits SAPK/JNK signal pathway in vivo. Front. Biosci. 11:2714-24
144. Alonso A, Rahmouni S, Williams S, van Stipdonk M, Jaroszewski L, et al. 2003. Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat. Immunol. 4:44-48
145. Cerignoli F, Rahmouni S, Ronai Z, Mustelin T. 2006. Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle 5:2210-15
146. Alonso A, Merlo JJ, Na S, Kholod N, Jaroszewski L, et al. 2002. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J. Biol. Chem. 277:5524-28
147. Marti F, Krause A, Post NH, Lyddane C, Dupont B, et al. 2001. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J. Immunol. 166:197-206
148. Perco P, Blaha P, Kainz A, Mayer B, Hauser P, et al. 2006. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl. Int. 19:146-57
149. Tautz L, Pellecchia M, Mustelin T. 2006. Targeting the PTPome in human disease. Expert Opin. Ther. Targets 10:157-77
150. Pellecchia M, Becattini B, Crowell KJ, Fattorusso R, Forino M, et al. 2004. NMR-based techniques in the hit identification and optimisation processes. Expert Opin. Ther. Targets 8:597-611
151. Syed AA, Simmonds MJ, Brand OJ, Franklyn JA, Gough SC, Heward JM. 2007. Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy. Clin. Endocrinol. In press
152. Pao LI, Lam KP, Henderson JM, Kutok JL, Alimzhanov M, et al. 2007. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27:35-48